Artwork

Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Improving Symptoms, Function, and Weight Loss in HFpEF Patients with Obesity

 
Share
 

Manage episode 389359576 series 1021437
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Javed Butler, MD, MBA, MPH
There’s no approved therapies specifically targeting obesity and HFpEF, but based on the STEP-HFpEF study that was presented at the 2023 ESC Congress, the treatment option semaglutide improves heart failure-related symptoms, physical function, and weight loss among patients with HFpEF and obesity. Here to walk through the study’s key findings with Dr. Mary Katherine Cheeley is fellow ReachMD host, Dr. Javed Butler, President of Baylor Scott and White Research Institute in Dallas, Texas.

  continue reading

183 episodes

Artwork
iconShare
 
Manage episode 389359576 series 1021437
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Javed Butler, MD, MBA, MPH
There’s no approved therapies specifically targeting obesity and HFpEF, but based on the STEP-HFpEF study that was presented at the 2023 ESC Congress, the treatment option semaglutide improves heart failure-related symptoms, physical function, and weight loss among patients with HFpEF and obesity. Here to walk through the study’s key findings with Dr. Mary Katherine Cheeley is fellow ReachMD host, Dr. Javed Butler, President of Baylor Scott and White Research Institute in Dallas, Texas.

  continue reading

183 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide